Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation

J Novak, J Dobrovolny, J Brozova, L Novakova… - Clinical and …, 2016 - Springer
J Novak, J Dobrovolny, J Brozova, L Novakova, T Kozak
Clinical and experimental medicine, 2016Springer
Immune reconstitution after high-dose chemotherapy and stem cell transplantation plays a
key role in restoring immunocompetence including defense against infection, immune
regulation, and onco-immune surveillance. In this work, we examined the recovery of
mucosal-associated invariant T (MAIT) cells, recently discovered innate-like T cells, after
various types of myeloablative chemotherapy and autologous peripheral blood stem cell
transplantation in 29 patients. We show that MAIT cells are relatively resistant to …
Abstract
Immune reconstitution after high-dose chemotherapy and stem cell transplantation plays a key role in restoring immunocompetence including defense against infection, immune regulation, and onco-immune surveillance. In this work, we examined the recovery of mucosal-associated invariant T (MAIT) cells, recently discovered innate-like T cells, after various types of myeloablative chemotherapy and autologous peripheral blood stem cell transplantation in 29 patients. We show that MAIT cells are relatively resistant to myeloablative conditioning. The median amount of MAIT cells rises to 43 % around day +30 and is sustained through further measurements on days +60 and +100. Moreover, MAIT cell recovery reaches 100 % of pre-treatment values in 33 % of patients already by day +60. The only factor affecting recovery of MAIT cells is age, younger age being associated with earlier MAIT cell recovery. The pre-treatment quantity of MAIT cells carries a prognostic impact on the early post-transplantation course. Patients with high levels of MAIT cells pre-treatment have significantly lower peak CRP levels (79.45 vs. 150 mg/L) post-treatment, reflecting a clinical trend of less severe infectious complications (less febrile days and less days on intravenous antibiotics). Altogether these data suggest that a high proportion of MAIT cells survive myeloablative chemotherapy and maintain their capacity to fight against infections probably on mucosal surfaces.
Springer